Injection site erythema: FDA reporting patterns
121,811 FDA FAERS reports mention Injection site erythema. 19,860 reports have a serious outcome flag.
Medicines named as suspect
- Etanercept: 41,000 reports
- Adalimumab: 16,186 reports
- Dupilumab: 10,907 reports
- Tirzepatide: 5,141 reports
- Teriparatide: 5,023 reports
- Interferon Beta-1a: 3,751 reports
- Glatiramer: 2,822 reports
- Ixekizumab: 2,190 reports
- Evolocumab: 1,868 reports
- Exenatide: 1,620 reports
- Dulaglutide: 1,575 reports
- Interferon Beta-1b: 1,574 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.